IND Approvals: Two of CMS’s Innovative Drugs Highly Selective TYK2 Inhibitor CMS-D001 and GnRH Receptor Antagonist CMS-D002 are approved for Drug Clinical Trials

Company News

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that CMS-D001 tablets (“CMS-D001”) and CMS-D002 capsules (“CMS-D002”) self-developed by the Group have been granted approvals for drug clinical trials recently by National Medical Products Administration of the People’s Republic of China (“NMPA”). NMPA agrees to conduct (i) a randomized, double-blind, placebo-controlled phase I clinical study of single or multiple dose escalation and food effects (open) to evaluate the safety, tolerability, pharmacokinetics and efficacy of CMS-D001 in healthy subjects and patients with plaque psoriasis; and (ii) a randomized, double-blind, placebo-controlled phase I clinical study of single or multiple dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D002 in healthy adult premenopausal female subjects.



CMS-D001 is a highly selective TYK2 (tyrosine kinase 2) inhibitor. TYK2 is a member of the JAK kinase family, which is an important component in immune cell signaling. CMS-D001 specifically inhibits the activation of TYK2 and blocks cell signal transduction mediated by inflammatory cytokines such as IL-23, IL-12 and Type I interferons [1], thereby inhibiting the pathological processes of autoimmunity and inflammation. Selective TYK2 inhibitors can reduce the impact on other JAK family kinases and reduce adverse effects while maintaining efficacy [2]. CMS-D001 is planned to be developed in the future for the treatment of immune-inflammatory diseases such as psoriasis[3], atopic dermatitis[4], and systemic lupus erythematosus[5].


Psoriasis is an immune-mediated chronic, relapsing, inflammatory, and systemic disease induced by a combination of genetics and environment. The clinical manifestations are scaly erythema or plaques, localized or widely distributed. Psoriasis can be combined with systemic diseases, seriously affecting the patient’s quality of life[6]. The incidence rate of psoriasis in China is approximately 0.47%[7], with more than 7 million psoriasis patients. Despite the availability of effective systemic treatment options, many patients with moderate to severe psoriasis remain undertreated or untreated or are dissatisfied with available therapies. Oral small molecule drugs, especially TYK2 inhibitors, have become a research hotspot in recent years due to the potential high efficacy, good safety and convenience. The preclinical data of CMS-D001 shows that the drug is expected to become an oral drug with reliable efficacy and good safety, providing patients with better treatment options.



CMS-D002 is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist. GnRH is a decapeptide hormone synthesized by hypothalamus and is an important factor in regulating hormone release in the reproductive system. CMS-D002 competes with endogenous GnRH to bind to the GnRH receptor on the pituitary gland, blocking the pituitary gonadal axis at the central nervous system level, reducing the release of endogenous FSH and LH, thereby inhibiting the secretion of downstream estrogen, progesterone and testosterone, alleviating the progression of sex hormone-related diseases[8]. CMS-D002 has shown excellent efficacy and safety in preclinical research and can be developed to treat endometriosis, uterine fibroids, prostate cancer and other diseases in the future.


Endometriosis refers to the occurrence, growth, infiltration, and repeated bleeding of endometrial tissue (glands and stroma) in the endometrium covering the uterine cavity and in parts other than the uterus,which in turn causes pain,infertility, nodules or masses, etc[9]. Endometriosis is extensive lesions, diverse shapes, and extremely aggressive and recurring. It is characterized by sex hormone dependence. It is one of the main causes of dysmenorrhea, infertility and chronic pelvic pain. Not only does it have a negative impact on patients’ quality of life, but it also places a significant burden on social health resources. Endometriosis is common in women of childbearing age. According to literature reports, about 10% of women of childbearing age suffer from endometriosis. There are about 300 million women of childbearing age in China aged 15-49[10], with about 30 million endometriosis patients. The use of various drugs for sequential treatment is the trend in long-term drug treatment of endometriosis. However, the clinical application of various drugs often leads to unsatisfactory efficacy, inconvenient administration routes and/or intolerable side effects, which limits the clinical application. Compared with existing drugs, non-peptide GnRH antagonists are oral dosage forms, which are easy to take and have no ignition effect in the initial stage of administration. They can quickly suppress estrogen levels after use, thereby quickly alleviating clinical symptoms, and have obvious advantages in the treatment of endometriosis[11]. Compared with GnRH receptor agonists used to treat similar diseases, small molecule GnRH receptor antagonists have a dose-dependent ability to inhibit sex hormones, and gonadal function can be quickly restored after drug withdrawal, improving patient compliance[12]. As an oral non-peptide small molecule GnRH receptor inhibitor, CMS-D002, combined with its excellent preclinical performance, is expected to provide patients with better treatment options.





1.Schwartz DM, et al. Nat Rev Drug Discov. 2017 Dec;16(12):843-862

2.Krueger JG, et al. J Am Acad Dermatol. 2022 Jan;86(1):148-157

3.Ghoreschi K, et al. Lancet. 2021 Feb 20;397(10275):754-766

4.Kreins AY, et al. J Exp Med. 2015 Sep 21;212(10):1641-62

5.Banerjee S, et al. Drugs. (2017) 77:521–46

6.Guideline for the Diagnosis and Treatment of Psoriasis in China (2023 Edition). Chinese Journal of Dermatology, 2023, 56 (7):573-625

7.Xiaolan Ding, Tinglin Wang, Yiwei Shen, et al. The Chinese Journal of Dermatovenereology, 2010,24 (7):598-601

8.Shi J, et al. Front Pharmacol. 2023 Jun 21;14:1199010

9.《Guideline for the Diagnosis and Treatment of Endometriosis (Third Edition). Chinese Journal of Obstetrics and Gynecology, 2021, 56 (12):812-824

10.2020 China Population Census Data

11.Xiaomeng Hou, Chao Peng, Yingfang Zhou. Chinese Journal of Obstetrics and Gynecology, 2023, 58(1)70-73

12.Jacques Donnez, et al. Int J Mol Sci. 2021 Oct 20;22(21):11342



1. This news/article is intended to share cutting-edge medical information and is only for reference by medical and health professionals for academic purposes. It is not intended to promote any products to you and is not for advertising purposes.

2. This news/article does not recommend any drugs, medical devices and/or indications.

3. The information involved in this news/article is for reference only. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.